SOLVAY AND MAYO CLINIC COLLABORATE ON CONCEPT FOR TREATING GASTROINTESTINAL MOTILITY DISORDERS

Solvay Pharmaceuticals, Inc. announced today that it has signed a collaboration agreement with the Mayo Foundation for Medical Education and Research to investigate a novel mechanism of action to treat gastrointestinal motility disorders. Mayo granted licenses to Solvay Pharmaceuticals to use its patent rights for the development of products, processes and methods for public use for this mechanism of action. Once Mayo has completed confirmatory studies on the concept, the company will collaborate with Mayo to screen Solvay Pharmaceuticals' pipeline molecules to identify those with a high affinity toward this mechanism of action.

Business Wire (http://home.businesswire.com/portal/site/google/index.jsp?ndmViewId=news_view&newsId=20050804005032&newsLang=en)